KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) EBITDA Margin (2017 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed EBITDA Margin for 16 consecutive years, with 5.1% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA Margin fell 2670.0% year-over-year to 5.1%, compared with a TTM value of 7.92% through Dec 2025, down 948.0%, and an annual FY2025 reading of 12.71%, down 425.0% over the prior year.
  • EBITDA Margin was 5.1% for Q4 2025 at Biomarin Pharmaceutical, down from 2.59% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 21.6% in Q4 2024 and bottomed at 14.65% in Q4 2021.
  • Average EBITDA Margin over 5 years is 7.61%, with a median of 8.01% recorded in 2023.
  • The sharpest move saw EBITDA Margin tumbled -16667bps in 2021, then surged 1511bps in 2024.
  • Year by year, EBITDA Margin stood at 14.65% in 2021, then surged by 83bps to 2.43% in 2022, then surged by 366bps to 6.48% in 2023, then soared by 233bps to 21.6% in 2024, then tumbled by -124bps to 5.1% in 2025.
  • Business Quant data shows EBITDA Margin for BMRN at 5.1% in Q4 2025, 2.59% in Q3 2025, and 21.42% in Q2 2025.